1000053-23-5

Basic information

• Product Name: TERT-BUTYL 4-(4-AMINO-2-FLUOROPHENYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE
• Synonyms: TERT-BUTYL 4-(4-AMINO-2-FLUOROPHENYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE;tert-Butyl (1-(4-aMino-2-fluorophenyl)piperidin-4-yl)carbaMate
• CAS NO: 1000053-23-5
• Molecular Formula: C₁₆H₂₄FN₃O₂
• Molecular Weight: 295.35
• Mol File: 1000053-23-5.mol
• Article Data: 4

Chemical Properties

• Melting Point: 110-113°C
• Boiling Point: 478.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.18±0.1 g/cm3(Predicted)
• PKA: 12.25±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-(4-AMINO-2-FLUOROPHENYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(4-AMINO-2-FLUOROPHENYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE(1000053-23-5)
• EPA Substance Registry System: TERT-BUTYL 4-(4-AMINO-2-FLUOROPHENYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE(1000053-23-5)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• HazardClass: IRRITANT
• Hazardous Substances Data: 1000053-23-5(Hazardous Substances Data)

Usage

General Description

TERT-BUTYL 4-(4-AMINO-2-FLUOROPHENYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE is a chemical compound with the molecular formula C17H23N3O2F. It is a tetrahydro pyrazinecarboxylate derivative that contains a tert-butyl group, an amino group, and a fluorophenyl group. This chemical is commonly used in the pharmaceutical industry for the synthesis of potential drug candidates, particularly in the development of new medications for various medical conditions. Its specific applications and potential uses are subject to ongoing research and development.

InChI:InChI=1S/C15H22FN3O2/c1-15(2,3)21-14(20)19-8-6-18(7-9-19)13-5-4-11(17)10-12(13)16/h4-5,10H,6-9,17H2,1-3H3

Upstream product

• 952901-82-5 [3-fluoro-4-(4-aminopiperidino)]nitrobenzene 
• 392660-18-3 3-fluoro-4-((4-BOC-amino)piperidino)nitrobenzene 
• 13035-19-3 4-aminopiperidine 
• 369-34-6 3,4-difluoronitrobenzene 

Downstream Products

• 1000054-72-7 {1-[4-(5-bromo-2-hydroxybenzoylamino)-2-fluorophenyl]piperidin-4-yl}carbamic acid tert-butyl ester 
• 1000054-09-0 (1-{4-[5-chloro-2-(2-methoxyethoxymethoxy)benzoylamino]-2-fluorophenyl}piperidin-4-yl)carbamic acid tert-butyl ester 
• 1229016-85-6 2-[3-fluoro-4-(4-BOC-aminopiperidino)phenylamino]-6-chloro-3-nitropyridine 
• 1229015-93-3 2-{[3-fluoro-4-(4-aminopiperidino)]phenyl-amino}-6-(methylamino)-3-nitropyridine 
• 1229016-96-9 2-{3-fluoro-4-[(4-BOC-amino)-piperidino]phenylamino}-6-(methylamino)-3-nitropyridine 

Relevant articles and documents

Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms

Herein, we describe the design, synthesis, and structure-activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivatives that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases. These screening cascades revealed that 18e was a preferred compound, with IC50 values of 0.7 and 4 nM for JAK2 and FLT3, respectively. Moreover, 18e was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, respectively, and possessed an excellent selectivity profile over the other 100 representative kinases. In a series of cytokine-stimulated cell-based assays, 18e exhibited a higher JAK2 selectivity over other JAK isoforms. The oral administration of 60 mg/kg of 18e could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, respectively. Additionally, 18e showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 inhibitory activity, suggesting that 18e might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-internal tandem duplication-driven acute myelogenous leukemia.

NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME

The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing the same, and a pharmaceutical composition including the same for prevention and treatment of osteoporosis. The 2,6-substituted-3-nitropyr